首頁 › 急性髓系白血病 › 堪薩斯 › Kansas City
Kansas City, KS 的 急性髓系白血病 臨床試驗
12 項針對 急性髓系白血病 的研究正在 Kansas City（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
招募中2 期
- University of Kansas Cancer Center, Kansas City
Ivosidenib as Post-HSCT Maintenance for AML
招募中2 期
- Kansas University Medical Center, Kansas City
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中觀察性研究歡迎健康志工
- Veteran Administration Eastern Kansas Healthcare, Leavenworth · 距離 21 英里
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
招募中2 期
- University of Kansas Cancer Center, Kansas City
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
招募中2 期
- University of Kansas Cancer Center, Kansas City
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
招募中2 期
- University of Kansas Cancer Center, Kansas City
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
招募中2 期
- University of Kansas Cancer Center, Kansas City
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
招募中3 期
- US-Kansas City KS-KUMC, Kansas City
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
招募中1 期
- University of Kansas Cancer Center, Kansas City
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
招募中1 期
- The University of Kansas Cancer Center, Kansas City
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
招募中1 期
- University of Kansas Medical Center Research Institute, Inc., Kansas City
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
招募中1 期
- KU Cancer Center, Kansas City
其他城市的 急性髓系白血病 試驗
- Houston, TX85 項研究
- New York City, NY51 項研究
- Boston, MA44 項研究
- Seattle, WA41 項研究
- Baldwin Park, CA40 項研究
- Columbus, OH35 項研究
- Philadelphia, PA34 項研究
- Durham, NC33 項研究
- Atlanta, GA31 項研究
- Tampa, FL29 項研究
- Chicago, IL26 項研究
- Portland, OR25 項研究
Kansas City 的其他研究
- 心血管疾病14 項研究
- 心臟衰竭13 項研究
- 肥胖症13 項研究
- 間質性肺病13 項研究
- 囊腫性纖維化13 項研究
- 乳癌12 項研究
- 膀胱癌12 項研究
- 前列腺癌12 項研究
- 非小細胞肺癌11 項研究
- 肺癌11 項研究
- 慢性阻塞性肺病9 項研究
- 氣喘8 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。